{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:40:10Z","timestamp":1749559210056,"version":"3.41.0"},"reference-count":11,"publisher":"Gobierno de Navarra","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An Sist Sanit Navar"],"published-print":{"date-parts":[[2019,4,25]]},"DOI":"10.23938\/assn.0392","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T10:15:31Z","timestamp":1549016131000},"page":"75-78","source":"Crossref","is-referenced-by-count":0,"title":["Blinatumomab as a bridge to trasplantation in refractory Philadelphia chromosome negative b-cell acute lymphoblastic leukemia: a case report"],"prefix":"10.23938","volume":"42","member":"10024","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-15-0125","article-title":"Blinatumomab for the treatment of philadelphia chromosome-negative, precursor b-cell acute lymphoblastic leukemia","volume":"21","author":"WOLACH","year":"2015","unstructured":"1. WOLACH O, STONE RM. Blinatumomab for the treatment of philadelphia chromosome-negative, precursor b-cell acute lymphoblastic leukemia. Clin Cancer Res 2015; 21: 4262-4269.","journal-title":"Clin Cancer Res"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"TOPP","year":"2014","unstructured":"2. TOPP MS, G\u00d6KBUGET N, ZUGMAIER G, KLAPPERS P, STELLJES M, NEUMANN S et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 4134-4140.","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/2040620716640422","article-title":"The role of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"7","author":"JE","year":"2016","unstructured":"3. BENJAMIN JE, STEIN AS. The role of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia. Ther Adv Hematol 2016; 7: 142-156.","journal-title":"Ther Adv Hematol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. PORTELL CA, WENZELL CM, ADVANI AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acutelymphoblastic leukemia. Clin Pharmacol 2013; 12; 5: 5-11.","DOI":"10.2147\/CPAA.S42689"},{"key":"ref4","unstructured":"5. European Medicines Agency. Ficha t\u00e9cnica de Blinatumomab (Blincyto\u00ae). https:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20151123133349\/anx_133349_es.pdf. Consultado el 2 de octubre de 2018."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. G\u00d6KBUGET N, DOMBRET H, BONIFACIO M, REICHLE A, GRAUX C, FAUL C et al. Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia. Blood 2018; 22.","DOI":"10.1182\/blood-2017-08-798322"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1038\/bmt.2017.186","article-title":"Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation","volume":"52","author":"Y1","year":"2017","unstructured":"7. ZENG Y1, KATSANIS E. Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation. Bone Marrow Transplant 2017; 52: 1671-1673.","journal-title":"Bone Marrow Transplant"},{"key":"ref7","unstructured":"8. Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia. Grupo Programa Espa\u00f1ol para el Tratamiento de las Hemopat\u00edas Malignas. Protocolo LAL-AR\/2011 (versi\u00f3n 5 de julio de 2013) para el tratamiento de la leucemia aguda linfobl\u00e1stica de alto riesgo bcr\/abl negativa en adultos. https:\/\/www.sehh.es\/images\/stories\/recursos\/pethema\/protocolos\/LAL\/LAL_AR_2011version-5-7-2013.pdf."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"ZUGMAIER","year":"2015","unstructured":"9. ZUGMAIER G, G\u00d6KBUGET N, KLINGER M, VIARDOT A, STELLJES M, NEUMANN S et al. Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood 2015; 126: 2578-2584.","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. FOLAN SA, REXWINKLE A, AUTRY J, BRYAN JC. Blinatumomab: bridging the gap in adult relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2016; 16: S2-5.","DOI":"10.1016\/j.clml.2016.02.001"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"MARTINELLI","year":"2017","unstructured":"11. MARTINELLI G, BOISSEL N, CHEVALLIER P, OTTMANN O, G\u00d6KBUGET N, TOPP MS et al. Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 2017; 35: 1795-1802.","journal-title":"J Clin Oncol"}],"container-title":["Anales del Sistema Sanitario de Navarra"],"original-title":[],"link":[{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/68490\/43579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:17:49Z","timestamp":1749557869000},"score":1,"resource":{"primary":{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/68490\/43579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,4]]}},"URL":"https:\/\/doi.org\/10.23938\/assn.0392","relation":{},"ISSN":["1137-6627"],"issn-type":[{"type":"print","value":"1137-6627"}],"subject":[],"published":{"date-parts":[[2019,4,25]]}}}